In the NAFLD animal model, hepatic GLP-1R expression levels at the NAFL (8 weeks) and NASH (16 weeks) stages were downregulated, consistent with the data in humans. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.